Compare NBY & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBY | SBFM |
|---|---|---|
| Founded | 2000 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 6.7M |
| IPO Year | 2007 | N/A |
| Metric | NBY | SBFM |
|---|---|---|
| Price | $1.07 | $1.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 116.4K | 83.3K |
| Earning Date | 11-07-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | $10,302,000.00 | ★ $37,323,742.00 |
| Revenue This Year | $23.91 | $10.26 |
| Revenue Next Year | $32.05 | $32.63 |
| P/E Ratio | $41.19 | ★ N/A |
| Revenue Growth | ★ 390.34 | 13.24 |
| 52 Week Low | $0.46 | $1.17 |
| 52 Week High | $4.44 | $3.90 |
| Indicator | NBY | SBFM |
|---|---|---|
| Relative Strength Index (RSI) | 48.92 | 41.31 |
| Support Level | $1.00 | $1.38 |
| Resistance Level | $1.11 | $1.50 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 84.28 | 40.54 |
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.